- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03145896
The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients
Study Overview
Detailed Description
Crohn's disease (CD) and ulcerative colitis (UC) are chronic gastrointestinal diseases characterized by relapsing and remitting inflammation of the intestines . Anemia may often complicate the course of inflammatory bowel disease (IBD) . A recent systematic review showed that anemia is common and may affect roughly 17% of patients with IBD .
The cause of anemia in IBD is multifactorial. The most common cause for anemia in IBD patients is iron deficiency anemia (IDA) secondary to increased blood loss from inflamed gastrointestinal mucosa and impaired absorption of iron. The anemia can be macrocytic due to impaired absorption of other nutrients including folate and cobalamin. Other causes are anemia due to medication (such as sulfasalazine) and anemia of chronic disease (ACD) .
ACD is characterized by normochromic, normocytic or mildly microcytic erythrocytes, low or normal serum iron and total iron-binding capacity, normal or increased iron stores reflected by elevated ferritin levels, low transferrin levels, and an inappropriately low reticulocyte response relative to the degree of anemia. ACD is unresponsive to treatment with iron, vitamin B12 or folic acid.
In the chronically ill patients, it has been described that the mechanism underlying anemia involves hepcidin.
Hepcidin, a β-defensin-like antimicrobial peptide, is part of the innate immune system and thus constitutes the first-line defense against infections. In vivo and in vitro studies have demonstrated that hepcidin is active against Gram-positive and Gram-negative bacteria as well as yeasts . In addition to its antimicrobial activity, it acts as an iron regulatory hormone. Increased hepcidin synthesis inhibits iron flow into plasma from macrophages that have taken up and degraded senescent erythrocytes as well as their hemoglobin, and also from small intestinal epithelial cells involved in the absorption of dietary iron . This iron release from cytoplasmic stores is prevented by binding of hepcidin to the iron exporter protein ferroportin. Ferroportin is internalized and degraded upon hepcidin activity.
Hepcidin is produced and secreted mainly by hepatocytes, and to a lesser extent by macrophages and adipocytes . Its synthesis is regulated by iron, erythropoietic activity and inflammation . Hepcidin expression is down-regulated in anemia with concomitant iron deficiency. Thus, ferroportin is not internalized from the cell membrane and iron can be transported from stores to the plasma to provide heme synthesis and erythropoiesis with more iron. On the other hand during anemia of chronic diseases (without significant iron deficiency), hepcidin expression is even increased, which may explain why iron is "trapped" intracellularly under these conditions.
In IBD (similar to other chronic inflammatory disease or infections), it can be assumed that inflammation increases hepcidin expression and synthesis as hepcidin also is an "acute phase protein" . This induction of hepcidin protein synthesis is at least partially mediated by interleukin-6 via its receptor and subsequent intracellular signal transduction via signal transducer and activator of transcription-3 (STAT3).
In the study of Pantelis et el it was found that the median hepcidin level were significantly higher in patients with IBD compared with healthy controls In a recent study by Basseri and coworkers, a positive correlation between serum hepcidin and IL-6 levels in IBD patients was confirmed. The authors further detected a negative correlation between serum hepcidin concentration and Hgb levels.
A potential mechanism underlying anemia during an chronic disease is suggested by recent data demonstrating a hepcidin lowering effect of vitamin D.
In the setting of chronic kidney disease patients, it was shown that vitamin D is inversely associated with hepcidin concentrations, and positively associated with hemoglobin and iron concentrations. Importantly, vitamin D has been reported to decrease inflammatory cytokines implicated in the pathophysiology of anemia during inflammation, and suppress expression of hepcidin mRNA. Additionally, oral administration of vitamin D in healthy adult volunteers lowered serum levels of hepcidin by 50% compared to baseline levels within 24 hours and persisted for 72 hours.
These initial results seem promising; but thus far the association between IBD, vitamin D status and anemia has never been established in the pediatric population, nor has the connection between these hormones and the efficacy of iron supplementation therapy. Controlled studies are warranted to determine this link and, thereafter, investigate the possible therapeutic potential of vitamin D supplementation
Aim:
To examine the association between hepcidin, IL6, vitamin D and anemia in children and adolescence with IBD and to study the possible effect of vitamin D supplementation on hepcidin level in IBD patients.
Hypothesis:
We hypothesize that in patients with parameters of anemia of chronic disease hepcidine level will be high and vitamin D level will be low. Supplementation of vitamin D will lower hepcidin levels and improve the anemia.
Study population and study design:
This is a prospective study. It will take place in the Pediatric Gastroenterology Unit at Dana- Dwek Children's hospital.
The study population will consists of 40 newly diagnosed IBD Patients, male and female, age 6-18. We will recruit all patients that are suspicious to have IBD based on their clinical and laboratory evaluation in their first diagnostic colonoscopy.
Each participant in the study will provide written informed consent at the beginning of the study.
We will document the participant's age, sex, anthropometric measurements (weight, height).
Each participant will complete a questionnaire that records personal lifestyle and demographic information, physical activity and sun exposure. Medical data (medical background, medication, sign and symptoms, severity of disease) will be collected from the patient's medical file.
We will take from each participant blood sample (approximately 10cc), to test levels of 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin, hematocrit (Hct), RBC, MCV, RDW, serum iron, total-iron-binding capacity, hepcidin, transferrin, soulable transferrin receptor, ferritin and IL6. We will document calprotectin level if available.
Before discharge home all patients will be taught to take 5000 unit of vitamin D (25(OH)D) daily, for the next 2 week . All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin, hematocrit (Hct), RBC, MCV, RDW, serum iron, total-iron-binding capacity, hepcidin, transferrin, ferritin soulable transferrin receptor and IL6.
All the data will be coded and the questionnaires will be kept in a locked place.
The concentration of 25(OH)D will be measured by radioimmunoassay. Levels of Hepcidin will be measured by a commercial kit.
Blood sample collection and questionnaire completion will be done in 2 days. (Visits will be appointed as the usual appointments after endoscopy in our clinic).
Study data analysis will be completed within a year.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with newly diagnosed IBD based on histopathology.
Exclusion Criteria:
- Patients that their histopathology will confirm eventually different diagnosis.
- Participants that are receiving medications known to alter vitamin D metabolism or have hepatic or renal disease
- Participants that suffer from hemoglobinopaties, bone marrow failure, or receive bone marrow suppressing agents
- Participants that went through a recent surgical procedure, or needed blood transfusion for any reason
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: IBD patients with Vitamin D treatment
|
After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week.
All patients will be invited for follow-up in 2 weeks to get the histopathology result.
In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin.
a control group will not take the Vitamin D supplements.
|
No Intervention: IBD patients with no Vitamin D treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
influence of vitamin D on anemia of inflammation
Time Frame: 2 weeks
|
levels of hepcidin, IL6, vitamin D and anemia in children and adolescence with newly diagnosed IBD before and after vitamin D supplemntation.
|
2 weeks
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ruchala P, Nemeth E. The pathophysiology and pharmacology of hepcidin. Trends Pharmacol Sci. 2014 Mar;35(3):155-61. doi: 10.1016/j.tips.2014.01.004. Epub 2014 Feb 17.
- Bacchetta J, Zaritsky JJ, Sea JL, Chun RF, Lisse TS, Zavala K, Nayak A, Wesseling-Perry K, Westerman M, Hollis BW, Salusky IB, Hewison M. Suppression of iron-regulatory hepcidin by vitamin D. J Am Soc Nephrol. 2014 Mar;25(3):564-72. doi: 10.1681/ASN.2013040355. Epub 2013 Nov 7.
- Nemeth E, Rivera S, Gabayan V, Keller C, Taudorf S, Pedersen BK, Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004 May;113(9):1271-6. doi: 10.1172/JCI20945.
- Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002 Aug 8;347(6):417-29. doi: 10.1056/NEJMra020831. No abstract available.
- Gasche C. Anemia in IBD: the overlooked villain. Inflamm Bowel Dis. 2000 May;6(2):142-150; discussion 151. doi: 10.1097/00054725-200005000-00013.
- de la Morena F, Gisbert JP. [Anemia and inflammatory bowel disease]. Rev Esp Enferm Dig. 2008 May;100(5):285-93. Spanish.
- de Silva AD, Mylonaki M, Rampton DS. Oral iron therapy in inflammatory bowel disease: usage, tolerance, and efficacy. Inflamm Bowel Dis. 2003 Sep;9(5):316-20. doi: 10.1097/00054725-200309000-00005.
- Gisbert JP, Gomollon F. Common misconceptions in the diagnosis and management of anemia in inflammatory bowel disease. Am J Gastroenterol. 2008 May;103(5):1299-307. doi: 10.1111/j.1572-0241.2008.01846.x.
- Basseri RJ, Nemeth E, Vassilaki ME, Basseri B, Enayati P, Shaye O, Bourikas LA, Ganz T, Papadakis KA. Hepcidin is a key mediator of anemia of inflammation in Crohn's disease. J Crohns Colitis. 2013 Sep;7(8):e286-91. doi: 10.1016/j.crohns.2012.10.013. Epub 2012 Dec 6.
- Yapakci E, Tarcan A, Celik B, Ozbek N, Gurakan B. Serum pro-hepcidin levels in term and preterm newborns with sepsis. Pediatr Int. 2009 Apr;51(2):289-92. doi: 10.1111/j.1442-200X.2008.02688.x.
- Nemeth E, Ganz T. The role of hepcidin in iron metabolism. Acta Haematol. 2009;122(2-3):78-86. doi: 10.1159/000243791. Epub 2009 Nov 10.
- Ross SL, Tran L, Winters A, Lee KJ, Plewa C, Foltz I, King C, Miranda LP, Allen J, Beckman H, Cooke KS, Moody G, Sasu BJ, Nemeth E, Ganz T, Molineux G, Arvedson TL. Molecular mechanism of hepcidin-mediated ferroportin internalization requires ferroportin lysines, not tyrosines or JAK-STAT. Cell Metab. 2012 Jun 6;15(6):905-17. doi: 10.1016/j.cmet.2012.03.017.
- Dudkowiak R, Neubauer K, Poniewierka E. Hepcidin and its role in inflammatory bowel disease. Adv Clin Exp Med. 2013 Jul-Aug;22(4):585-91.
- Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003 Apr 1;101(7):2461-3. doi: 10.1182/blood-2002-10-3235. Epub 2002 Nov 14.
- Theurl I, Schroll A, Nairz M, Seifert M, Theurl M, Sonnweber T, Kulaksiz H, Weiss G. Pathways for the regulation of hepcidin expression in anemia of chronic disease and iron deficiency anemia in vivo. Haematologica. 2011 Dec;96(12):1761-9. doi: 10.3324/haematol.2011.048926. Epub 2011 Aug 22.
- Ferrucci L, Semba RD, Guralnik JM, Ershler WB, Bandinelli S, Patel KV, Sun K, Woodman RC, Andrews NC, Cotter RJ, Ganz T, Nemeth E, Longo DL. Proinflammatory state, hepcidin, and anemia in older persons. Blood. 2010 May 6;115(18):3810-6. doi: 10.1182/blood-2009-02-201087. Epub 2010 Jan 15.
- Oustamanolakis P, Koutroubakis IE, Messaritakis I, Malliaraki N, Sfiridaki A, Kouroumalis EA. Serum hepcidin and prohepcidin concentrations in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2011 Mar;23(3):262-8. doi: 10.1097/MEG.0b013e328343b885.
- Smith EM, Alvarez JA, Martin GS, Zughaier SM, Ziegler TR, Tangpricha V. Vitamin D deficiency is associated with anaemia among African Americans in a US cohort. Br J Nutr. 2015 Jun 14;113(11):1732-40. doi: 10.1017/S0007114515000999. Epub 2015 Apr 16.
- Moran-Lev H, Galai T, Yerushalmy-Feler A, Weisman Y, Anafy A, Deutsch V, Cipok M, Lubetzky R, Cohen S. Vitamin D Decreases Hepcidin and Inflammatory Markers in Newly Diagnosed Inflammatory Bowel Disease Paediatric Patients: A Prospective Study. J Crohns Colitis. 2019 Sep 27;13(10):1287-1291. doi: 10.1093/ecco-jcc/jjz056.
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TASMC-15-SC-0778-CTIL
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on IBD
-
Assiut UniversityNot yet recruiting
-
Johannes Gutenberg University MainzUnknownHealthy | IBDGermany
-
Nationwide Children's HospitalSuspended
-
Cedars-Sinai Medical CenterCompleted
-
Assiut UniversityUnknown
-
Atlantic Pharmaceuticals LtdCompleted
-
Aerpio TherapeuticsCompleted
-
Fundación de Investigación Biomédica - Hospital...Not yet recruitingDrusgs for IBDSpain
Clinical Trials on vitamin D
-
PfizerTerminated
-
Umeå UniversityRegion SkaneCompleted
-
Fundación Cardiovascular de ColombiaUniversidad Industrial de Santander; Farma de Colombia SACompletedVitamin D Deficiency | Overweight and Obesity | Overweight AdolescentsColombia
-
Khon Kaen UniversityNot yet recruiting
-
Nutrition Institute, SloveniaSlovenian Research Agency; Higher School of Applied Sciences (VIST); Valens Int...CompletedVitamin D DeficiencySlovenia
-
USDA, Western Human Nutrition Research CenterCompletedVitamin D DeficiencyUnited States
-
University of AarhusNot yet recruitingImmune System Diseases | Growth | Child Development | Vitamin D Supplementation
-
University Hospital, Basel, SwitzerlandCompleted
-
Cornell UniversityArogyavaram Medical CentreNot yet recruiting
-
Brigham and Women's HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting